1,366 reports of this reaction
1.2% of all NIRMATRELVIR AND RITONAVIR reports
#11 most reported adverse reaction
NASAL CONGESTION is the #11 most commonly reported adverse reaction for NIRMATRELVIR AND RITONAVIR, manufactured by Pfizer Laboratories Div Pfizer Inc. There are 1,366 FDA adverse event reports linking NIRMATRELVIR AND RITONAVIR to NASAL CONGESTION. This represents approximately 1.2% of all 110,406 adverse event reports for this drug.
NIRMATRELVIR AND RITONAVIR has an overall safety score of 75 out of 100. Patients taking NIRMATRELVIR AND RITONAVIR who experience nasal congestion should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NASAL CONGESTION is a less commonly reported adverse event for NIRMATRELVIR AND RITONAVIR, but still significant enough to appear in the safety profile.
In addition to nasal congestion, the following adverse reactions have been reported for NIRMATRELVIR AND RITONAVIR:
The following drugs have also been linked to nasal congestion in FDA adverse event reports:
NASAL CONGESTION has been reported as an adverse event in 1,366 FDA reports for NIRMATRELVIR AND RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
NASAL CONGESTION accounts for approximately 1.2% of all adverse event reports for NIRMATRELVIR AND RITONAVIR, making it a notable side effect.
If you experience nasal congestion while taking NIRMATRELVIR AND RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.